A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

ClinicalTrials.gov ID: NCT05329766

Public ClinicalTrials.gov record NCT05329766. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).

Study identification

NCT ID: NCT05329766
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Arcus Biosciences, Inc.; Industry
Enrollment: 332 participants

Conditions and interventions

Conditions

Gastrointestinal Tract Malignancies

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 10, 2022 (Actual)
Primary completion: Jan 2027 (Estimated)
Completion: Jun 2027 (Estimated)
Last update posted: Sep 29, 2026

2022 – 2027

United States locations

U.S. sites: 17
U.S. states: 12
U.S. cities: 15

Facility	City	State	ZIP	Site status
Research Site	Phoenix	Arizona	85054	—
Research Site	Los Angeles	California	90033	—
Research Site	Santa Monica	California	90024	—
Research Site	Derby	Connecticut	06418	—
Research Site	Fort Myers	Florida	33901	—
Research Site	Jacksonville	Florida	32224	—
Research Site	St. Petersburg	Florida	33705	—
Research Site	Boston	Massachusetts	02109	—
Research Site	New York	New York	10021-0005	—
Research Site	New York	New York	10032	—
Research Site	Durham	North Carolina	27710	—
Research Site	Columbus	Ohio	43219	—
Research Site	Oklahoma City	Oklahoma	73104	—
Research Site	Portland	Oregon	97213	—
Research Site	Nashville	Tennessee	37203	—
Research Site	Nashville	Tennessee	37232	—
Research Site	Fairfax	Virginia	22031	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05329766, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 29, 2026 · Synced Oct 19, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05329766 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →